● 本报记者 傅苏颖 作为从基层医药批发商成长起来的行业龙头，九州通正以"三新两化"战略重塑发展动能。 九州通董事长刘长云日前在接受中国证券报记者专访时表示，公司通过数字化转型赋能业务、管理、物 流全链条，推动医美等新兴业务快速增长，同时以"三化人才战略"广纳全球贤才，既着力破解流通行业 长期存在的"两不沾"困境，更在产品端突破、终端网络构建以及长效发展机制上持续发力，为实现"中 国最专业的大健康服务商"愿景及"百年老店"目标注入强劲动能。 谈及数字化推进策略，刘长云介绍，公司采用"需求驱动+项目制"模式。每年底各业务板块与职能部门 提报数字化需求，经管理层与IT团队从"必要性""可行性"双维度评审后立项，2025年计划落地45个项 目。目前公司拥有1500名左右IT工程师，并与阿里、腾讯、华为等外部企业合作，形成"有组织、有目 标、有落地"的数字化转型体系。 "数字化不仅是发展需求，更是企业生存的必备项。"刘长云认为，未来行业竞争的核心将是数字化与AI 智能化能力，公司将持续以项目为抓手，推动数字化在各业务场景的深度渗透，巩固行业智慧化领先优 势。 加码医美业务布局 数字化赋能 1985年，九州通创始人刘宝 ...

Group 1 - The core viewpoint indicates that Huaxi Biological (688363) has a strong overall score of 50.30, suggesting a robust performance in the market [1] - The main cost analysis shows that the current main cost is 51.41 yuan, with a 5-day average cost of 51.21 yuan and a 20-day average cost of 50.69 yuan, indicating a stable pricing trend [1] - The stock has not experienced any limit-up or limit-down events in the past year, reflecting a stable trading environment [1] Group 2 - The technical analysis identifies a short-term resistance level at 51.52 yuan and a support level at 50.35 yuan, indicating potential price fluctuations within this range [2] - The funding flow data for July 11, 2025, shows a net outflow of 723.83 million yuan from main funds, which is 5% of the total transaction volume, suggesting cautious market sentiment [2] - The related industry sectors, including beauty care, medical devices, cosmetics, and medical beauty, show minor percentage changes, indicating a relatively stable market environment [2]

Core Viewpoint - The IPO application of Beijing Plant Doctor Cosmetics Co., Ltd. has been accepted, indicating a growing acceptance of diverse business models in the cosmetics industry [1][3]. Group 1: Company Overview - Plant Doctor focuses on plant extraction and offers a range of cosmetics including lotions, creams, and serums, with projected revenues and net profits of 2.156 billion yuan and 243 million yuan respectively for 2024 [1]. - The company primarily expands its performance through authorized dealers who open offline specialty stores, with a total of 3,830 authorized stores expected by the end of 2024, generating 1.111 billion yuan, accounting for over 50% of total revenue [1][5]. - Plant Doctor's business model includes both direct-operated stores and authorized specialty stores, with direct-operated stores contributing nearly 25% to total revenue in 2024 [3]. Group 2: Financial Performance - By the end of 2024, Plant Doctor plans to have 498 direct-operated stores, generating 527 million yuan, with an average annual revenue of 1.0575 million yuan per store [4]. - The authorized specialty stores are the main revenue drivers, expected to generate 1.111 billion yuan in 2024, which is about 50% of total revenue [5]. - The average annual revenue per authorized store increased from 276,200 yuan in 2022 to 289,700 yuan in 2024, although the revenue per direct-operated store is 3.65 times higher than that of authorized stores [12][13]. Group 3: Market Strategy and Expansion - Plant Doctor's IPO aims to raise 998 million yuan for marketing and the establishment of research and development centers [1]. - The company has been expanding its offline presence rapidly, with a net increase of 170 authorized stores in 2023, pushing the total number of stores past 4,000 [10]. - Despite the rapid expansion, Plant Doctor has begun closing underperforming stores, reducing the number of authorized stores by 294 by the end of 2024 [11]. Group 4: Industry Context and Challenges - The acceptance of Plant Doctor's IPO comes amid a cautious regulatory environment for franchise and chain businesses, which may explain the company's avoidance of the term "franchise" in its prospectus [7][19]. - The company is also exploring the beauty salon business model, offering in-store services to enhance customer experience, which may signal a shift in its business strategy [17][18]. - Plant Doctor is diversifying its sales channels by establishing online platforms and collaborating with e-commerce giants, with online sales projected to reach 519 million yuan in 2024, accounting for nearly 25% of total revenue [18].

灼识咨询是一家知名咨询公司。其服务包括IPO行业咨询、商业尽职调查、战略咨询、专家网络服 务等。其咨询团队长期追踪消费品、互联网、大数据、高科技、能源电力、供应链、人工智能、 金融服务、医疗、教育、文娱、环境和楼宇科技、化工、物流、工业、制造业、农业等方面最新 的市场趋势，并拥有上述行业最相关且有见地的市场信息。 CIC灼识咨询 AI时代的 美妆个护变革 本文件提供的任何内容均系灼识咨询公司独有的高度机密性资料。 所有统计数据真实可靠，并是基于截至本报告发布日的可用信息。 若您希望获取CIC灼识咨询的详细资料、与灼识建立媒体/市场合作，或加入灼识行业交流群，欢 迎扫码，也可致函marketing@cninsights.com。 灼识咨询通过运用各种资源进行一手研究和二手研究。一手研究包括访谈行业专家和业内人士。 二手研究包括分析各种公开发布的数据资源，数据来源包括中华人民共和国国家统计局、上市公 司公告等。灼识咨询使用内部数据分析模型对所收集的信息和数据进行分析，通过对使用各类研 究方法收集的数据进行参考比对，以确保分析的准确性。 目录 1 2 行业变迁催生AI机遇：中国美妆个护市场现状分析 AI重塑美妆个护 ...

近日，罗丽芬控股旗下嘉文丽（福建）化妆品有限公司凭借"芙蓉植物衍生的高性能碳量子点及其芙蓉 霜应用研究"，在"2025个人护理品行业-荣格技术创新奖"评选中大放异彩，成功斩获殊荣。这一成就不 仅彰显了罗丽芬在生物质材料研发领域的卓越实力，更以科技硬实力推动美容行业向"纯净美容"与"可 持续美妆"赛道加速跃迁，为中国美业树立了绿色变革的新标杆。 罗丽芬研发团队以东方草药芙蓉植物为原料，采用靶向热解工艺提取出高性能碳量子点。该技术突破性 地将光热效应与抗氧化、保湿功能融合，形成"精准分解黑色素+靶向修护健康组织"的复合型功效矩 阵。实验数据显示，其祛斑效能显著优于传统成分，且全程采用无重金属催化剂的水热合成工艺，完美 契合全球消费者对"天然、高效、可持续"美妆产品的核心诉求。作为国家高新技术企业，罗丽芬控股始 终以"植物灵感×分子科技"为双轮驱动，构建起覆盖原料研发、技术创新到标准制定的全产业链优势。 目前，企业已拥有26项发明专利、32项实用新型专利，并通过CNAS认证及多项国际标准制定，持续夯 实行业技术壁垒。 此次获奖，是罗丽芬以科技创新撬动产业升级的里程碑式成果。在研发赛道上，企业正以"全域研发生 态"为 ...

Core Viewpoint - The National Health Commission emphasizes the importance of distinguishing between medical and non-medical beauty services, highlighting the risks associated with non-professional practices in medical aesthetics [1][2][3] Group 1: Medical vs. Non-Medical Aesthetics - Medical aesthetics involves invasive techniques such as surgeries and injections aimed at repairing or reshaping appearance, while non-medical beauty services are non-invasive, like applying face masks [1] - Medical institutions must meet strict regulatory requirements to ensure safety and quality in medical aesthetic services, which can be verified through the National Health Commission's official website [1] Group 2: Risks of Non-Medical Aesthetic Practices - Increased risk of infection due to non-sterile environments and improper handling in non-medical settings, potentially leading to severe complications like sepsis [2] - Higher likelihood of adverse reactions from unregulated injection materials, which may cause serious allergic reactions or other health issues [2] - Greater risk of embolism from injections performed by non-professionals, which can result in severe consequences such as skin necrosis, blindness, or stroke [2][3] - Non-medical institutions lack effective emergency response measures, making it difficult to address complications like allergies or embolisms promptly [3]

Group 1 - The stock of Haohai Biological Technology (688366) has a comprehensive score of 47.92, indicating a weak performance [1] - The main cost analysis shows that the current main cost is 50.41 yuan, with a 5-day main cost of 50.79 yuan and a 20-day main cost of 51.67 yuan [1] - There have been no instances of the stock hitting the upper or lower limits in the past year [1] Group 2 - On July 4, 2025, the net outflow of main funds was 387.01 million yuan, accounting for 12% of the total transaction amount [2] - The short-term pressure level is at 51.24 yuan, while the short-term support level is at 50.15 yuan [2] - The medical device sector showed a slight decline, with the medical device concept down by 0.40% and medical beauty down by 0.65% [2]

Core Insights - L'Oréal Group continues its acquisition strategy, recently acquiring the hair care brand Color Wow, following the acquisition of Medik8 earlier in June [1][3][4] Group 1: Acquisition Details - The acquisition of Color Wow was officially announced on June 30, with the financial details undisclosed. Color Wow will be integrated into L'Oréal's Professional Products Division [1][4] - Color Wow, founded in 2013 by Gail Federici, is recognized as one of the fastest-growing and most innovative professional hair care brands, boasting over 130 beauty awards [4][6] - The brand's products are priced between $24 and $46, making high-quality hair care accessible [4][6] Group 2: Strategic Implications - Omar Hajeri, President of L'Oréal's Professional Products Division, expressed confidence in Color Wow's potential to become a strong global brand [3][6] - The addition of Color Wow increases the number of brands in L'Oréal's Professional Products Division to ten, enhancing its product portfolio and global growth potential [6][9] Group 3: Market Trends - The acquisition reflects broader changes in the beauty industry, with a growing consumer demand for efficacy and ingredient transparency, particularly in hair and body care [3][12] - The global shampoo market is projected to grow to $56.54 billion by 2032, with an annual growth rate of 5.71%, indicating a rising interest in hair care products [13] - L'Oréal's Professional Products Division has seen consistent sales growth, with a notable increase of 24.8% in 2021, highlighting its importance to the company's overall performance [13][20] Group 4: Competitive Landscape - Other major players in the industry, such as Unilever and Henkel, are also expanding their presence in the hair care market through acquisitions, indicating a competitive environment [16][19] - The rise of domestic brands like Adolph and Lafang showcases the evolving landscape of the hair care market, emphasizing the need for innovation and differentiation [19][20]

Group 1 - The stock of Huaxi Biological (688363) has a comprehensive score of 48.01, indicating a weak performance [1] - The main cost analysis shows that the current main cost is 51.35 yuan, with a 5-day main cost of 51.43 yuan and a 20-day main cost of 52.60 yuan [1] - There have been no instances of the stock hitting the upper or lower limits in the past year [1] Group 2 - As of June 30, 2025, the net outflow of main funds is 118.96 million yuan, accounting for -1% of the total transaction amount [2] - The short-term pressure level is at 51.90 yuan, while the short-term support level is at 50.67 yuan [2] - The stock is associated with several sectors, including beauty care (0.52%), medical device concept (1.62%), cosmetics concept (0.51%), and medical beauty (1.20%) [2]

据抖音平台6 1 8好物节销售数据显示（2 0 2 5年5月1 3日- 6月1 8日累计销售额），半亩花田位居 抖音6 1 8好物节身体护理品牌热销榜To p 1。在中外大品牌云集的个人护理赛道，半亩花田以 毋庸置疑的实力再次交上一份满意的答卷。 美护"年中考"成绩揭晓！ 为什么是半亩花田？ 当美护产业步入深度调整期，剖析半亩花田的登顶之路，恰是为国货品牌锚定未来价值坐标的 绝佳样本。 《 中 国 身 体 皮 肤 护 理 白 皮 书 》 数 据 显 示 ， 过 去 的 5 年 里 ， 中 国 身 体 护 理 市 场 规 模 保 持 稳 定 增 长，2 0 2 5年市场规模有望突破3 0 0亿元。 在数字增长的背后，个人护理市场需求出现显著迭代：已完成从清洁到滋养功效，再到体验和 情绪价值的"三级跳"。功能、人群、肤质的细分，高端化、功效化、体验升级，折射出消费者 对个人护理品类的更高需求以及生活方式的更高追求。 图片来源：尼尔森IQ 全球美容创新报告 然而，纵观市面上的个人护理产品，大多常规化和同质化，远未满足个性化和多元化的需求。 拥有科研实力和创造力的个人护理品牌依然具有巨大的想象空间。 作为1 5年专注 ...